 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Variagenics, Inc.
 |
Variagenics, Inc. |
 |
 |
 |
PROFILE |
 |
Variagenics uses pharmacogenomics, which studies links between genetic variability (measured in single nucleotide polymorphisms, or SNPs) and response to drugs, to develop new drugs and diagnostic products. Products include the Variagenic Impact Program, which analyzes SNP data to identify drug targets, and the NuCleave DNA analysis platform, which performs assays on DNA samples to examine patients' responses to drugs. Initially focused on cancer, the company is now also targeting cardiovascular, neurological, and inflammatory diseases. Variagenics has clinical research collaborative agreements with Covance and Quintiles Transnational. The Sprout Group owns about 20% of the company.
COMPETITION |
 |
CuraGen Corporation (CRGN)
Human Genome Sciences, Inc. (HGSI)
Millennium Pharmaceuticals, Inc. (MLNM)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 2.30
1-Yr. Sales Growth: 475.0%
Employees: 89
Revenue per employee: $25,842.70
KEY PEOPLE |
 |
Taylor J. Crouch
CEO
Richard P. Shea
CFO
CONTACT INFO |
 |
60 Hampshire St.
Cambridge, MA 02139
US
Phone: 617-588-5300
Fax: 617-588-5399
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |